-
1
-
-
0027921638
-
Head and neck cancer
-
Vokes, E.E.; Weichselbaum, R.R.; Lippman, S.M.; Hong, W.K. Head and neck cancer. N. Engl. J. Med. 1993, 328, 184–194.
-
(1993)
N. Engl. J. Med
, vol.328
, pp. 184-194
-
-
Vokes, E.E.1
Weichselbaum, R.R.2
Lippman, S.M.3
Hong, W.K.4
-
2
-
-
0034651902
-
Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck
-
Adelstein, D.J.; Lavertu, P.; Saxton, J.P.; Secic, M.; Wood, B.G.; Wanamaker, J.R.; Eliachar, I.; Strome, M.; Larto, M.A. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000, 88, 876–883.
-
(2000)
Cancer
, vol.88
, pp. 876-883
-
-
Adelstein, D.J.1
Lavertu, P.2
Saxton, J.P.3
Secic, M.4
Wood, B.G.5
Wanamaker, J.R.6
Eliachar, I.7
Strome, M.8
Larto, M.A.9
-
3
-
-
0027254069
-
How many mutations are required for tumorigenesis? Implications from human cancer data
-
Renan, M.J. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog. 1993, 7, 139–146.
-
(1993)
Mol. Carcinog
, vol.7
, pp. 139-146
-
-
Renan, M.J.1
-
4
-
-
0028269349
-
Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region
-
Van Dyke, D.L.; Worsham, M.J.; Benninger, M.S.; Krause, C.J.; Baker, S.R.; Wolf, G.T.; Drumheller, T.; Tilley, B.C.; Carey, T.E. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 1994, 9, 192–206.
-
(1994)
Genes Chromosomes Cancer
, vol.9
, pp. 192-206
-
-
Van Dyke, D.L.1
Worsham, M.J.2
Benninger, M.S.3
Krause, C.J.4
Baker, S.R.5
Wolf, G.T.6
Drumheller, T.7
Tilley, B.C.8
Carey, T.E.9
-
5
-
-
84923197605
-
Comprehensive genomic characterization of head and neck squamous cell carcinomas
-
Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517, 576–582.
-
(2015)
Nature
, vol.517
, pp. 576-582
-
-
-
6
-
-
0033542145
-
Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma
-
Okami, K.; Reed, A.L.; Cairns, P.; Koch, W.M.; Westra, W.H.; Wehage, S.; Jen, J.; Sidransky, D. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999, 18, 3541–3545.
-
(1999)
Oncogene
, vol.18
, pp. 3541-3545
-
-
Okami, K.1
Reed, A.L.2
Cairns, P.3
Koch, W.M.4
Westra, W.H.5
Wehage, S.6
Jen, J.7
Sidransky, D.8
-
7
-
-
84929505977
-
Molecular biology and immunology of head and neck cancer
-
Guo, T.; Califano, J.A. Molecular biology and immunology of head and neck cancer. Surg. Oncol. Clin. N. Am. 2015, 24, 397–407.
-
(2015)
Surg. Oncol. Clin. N. Am
, vol.24
, pp. 397-407
-
-
Guo, T.1
Califano, J.A.2
-
9
-
-
84979673540
-
Molecular pathways in head and neck cancer: EGFR, PI3K, and more
-
Psyrri, A.; Seiwert, T.Y.; Jimeno, A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am. Soc. Clin. Oncol. Educ. Book 2013, 246–255.
-
(2013)
Am. Soc. Clin. Oncol. Educ. Book
, pp. 246-255
-
-
Psyrri, A.1
Seiwert, T.Y.2
Jimeno, A.3
-
10
-
-
84942190711
-
Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies
-
Pezzuto, F.; Buonaguro, L.; Caponigro, F.; Ionna, F.; Starita, N.; Annunziata, C.; Buonaguro, F.M.; Tornesello, M.L. Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. Oncology 2015, 89, 125–136.
-
(2015)
Oncology
, vol.89
, pp. 125-136
-
-
Pezzuto, F.1
Buonaguro, L.2
Caponigro, F.3
Ionna, F.4
Starita, N.5
Annunziata, C.6
Buonaguro, F.M.7
Tornesello, M.L.8
-
11
-
-
0034833599
-
Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions
-
Nagatsuka, H.; Ishiwari, Y.; Tsujigiwa, H.; Nakano, K.; Nagai, N. Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol. 2001, 37, 599–604.
-
(2001)
Oral Oncol
, vol.37
, pp. 599-604
-
-
Nagatsuka, H.1
Ishiwari, Y.2
Tsujigiwa, H.3
Nakano, K.4
Nagai, N.5
-
12
-
-
0036286452
-
Mutant epidermal growth factor receptors as targets for cancer therapy
-
Lorimer, I.A. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr. Cancer Drug Targets 2002,2, 91–102.
-
(2002)
Curr. Cancer Drug Targets
, vol.2
, pp. 91-102
-
-
Lorimer, I.A.1
-
13
-
-
0001744237
-
Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines
-
Rubin Grandis, J.; Zeng, Q.; Tweardy, D.J. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat. Med. 1996, 2, 237–240.
-
(1996)
Nat. Med
, vol.2
, pp. 237-240
-
-
Rubin Grandis, J.1
Zeng, Q.2
Tweardy, D.J.3
-
14
-
-
0033227225
-
Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage
-
Chen, B.K.; Ohtsuki, Y.; Furihata, M.; Takeuchi, T.; Iwata, J.; Liang, S.B.; Sonobe, H. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int. J. Oncol. 1999, 15, 893–898.
-
(1999)
Int. J. Oncol
, vol.15
, pp. 893-898
-
-
Chen, B.K.1
Ohtsuki, Y.2
Furihata, M.3
Takeuchi, T.4
Iwata, J.5
Liang, S.B.6
Sonobe, H.7
-
15
-
-
0037115674
-
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
-
Ang, K.K.; Berkey, B.A.; Tu, X.; Zhang, H.Z.; Katz, R.; Hammond, E.H.; Fu, K.K.; Milas, L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002, 62, 7350–7356.
-
(2002)
Cancer Res
, vol.62
, pp. 7350-7356
-
-
Ang, K.K.1
Berkey, B.A.2
Tu, X.3
Zhang, H.Z.4
Katz, R.5
Hammond, E.H.6
Fu, K.K.7
Milas, L.8
-
16
-
-
77950534860
-
EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy
-
Numico, G.; Russi, E.G.; Colantonio, I.; Lantermo, R.A.; Silvestris, N.; Vitiello, R.; Comino, A.; Abrate, M.; Zavattero, C.; Melano, A.; et al. EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res. 2010, 30, 671–676.
-
(2010)
Anticancer Res
, vol.30
, pp. 671-676
-
-
Numico, G.1
Russi, E.G.2
Colantonio, I.3
Lantermo, R.A.4
Silvestris, N.5
Vitiello, R.6
Comino, A.7
Abrate, M.8
Zavattero, C.9
Melano, A.10
-
17
-
-
0036076482
-
Genetic alterations in squamous cell carcinomas of the hypopharynx with correlations to clinicopathological features
-
Rodrigo, J.P.; Gonzalez, M.V.; Lazo, P.S.; Ramos, S.; Coto, E.; Alvarez, I.; Garcia, L.A.; Suarez, C. Genetic alterations in squamous cell carcinomas of the hypopharynx with correlations to clinicopathological features. Oral Oncol. 2002, 38, 357–363.
-
(2002)
Oral Oncol
, vol.38
, pp. 357-363
-
-
Rodrigo, J.P.1
Gonzalez, M.V.2
Lazo, P.S.3
Ramos, S.4
Coto, E.5
Alvarez, I.6
Garcia, L.A.7
Suarez, C.8
-
18
-
-
0034919864
-
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study
-
Crombet, T.; Torres, O.; Rodriguez, V.; Menendez, A.; Stevenson, A.; Ramos, M.; Torres, F.; Figueredo, R.; Veitia, I.; Iznaga, N.; et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study. Hybridoma 2001, 20, 131–136.
-
(2001)
Hybridoma
, vol.20
, pp. 131-136
-
-
Crombet, T.1
Torres, O.2
Rodriguez, V.3
Menendez, A.4
Stevenson, A.5
Ramos, M.6
Torres, F.7
Figueredo, R.8
Veitia, I.9
Iznaga, N.10
-
19
-
-
8944263458
-
Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
-
Modjtahedi, H.; Hickish, T.; Nicolson, M.; Moore, J.; Styles, J.; Eccles, S.; Jackson, E.; Salter, J.; Sloane, J.; Spencer, L.; et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 1996, 73, 228–235.
-
(1996)
Br. J. Cancer
, vol.73
, pp. 228-235
-
-
Modjtahedi, H.1
Hickish, T.2
Nicolson, M.3
Moore, J.4
Styles, J.5
Eccles, S.6
Jackson, E.7
Salter, J.8
Sloane, J.9
Spencer, L.10
-
20
-
-
0028819660
-
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
-
Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1, 1311–1318.
-
(1995)
Clin. Cancer Res
, vol.1
, pp. 1311-1318
-
-
Goldstein, N.I.1
Prewett, M.2
Zuklys, K.3
Rockwell, P.4
Mendelsohn, J.5
-
21
-
-
0029670014
-
Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
-
Wu, X.; Rubin, M.; Fan, Z.; DeBlasio, T.; Soos, T.; Koff, A.; Mendelsohn, J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996, 12, 1397–1403.
-
(1996)
Oncogene
, vol.12
, pp. 1397-1403
-
-
Wu, X.1
Rubin, M.2
Fan, Z.3
Deblasio, T.4
Soos, T.5
Koff, A.6
Mendelsohn, J.7
-
22
-
-
0035398021
-
Phase I study of anti—Epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
-
Robert, F.; Ezekiel, M.P.; Spencer, S.A.; Meredith, R.F.; Bonner, J.A.; Khazaeli, M.B.; Saleh, M.N.; Carey, D.; LoBulio, A.F.; Wheeler, R.H.; et al. Phase I study of anti—Epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 3234–3243.
-
(2001)
J. Clin. Oncol
, vol.19
, pp. 3234-3243
-
-
Robert, F.1
Ezekiel, M.P.2
Spencer, S.A.3
Meredith, R.F.4
Bonner, J.A.5
Khazaeli, M.B.6
Saleh, M.N.7
Carey, D.8
Lobulio, A.F.9
Wheeler, R.H.10
-
23
-
-
19244366949
-
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
-
Baselga, J.; Pfister, D.; Cooper, M.R.; Cohen, R.; Burtness, B.; Bos, M.; D'Andrea, G.; Seidman, A.; Norton, L.; Gunnett, K.; et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000, 18, 904–914.
-
(2000)
J. Clin. Oncol
, vol.18
, pp. 904-914
-
-
Baselga, J.1
Pfister, D.2
Cooper, M.R.3
Cohen, R.4
Burtness, B.5
Bos, M.6
D'andrea, G.7
Seidman, A.8
Norton, L.9
Gunnett, K.10
-
24
-
-
0033966576
-
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
-
Milas, L.; Mason, K.; Hunter, N.; Petersen, S.; Yamakawa, M.; Ang, K.; Mendelsohn, J.; Fan, Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 2000, 6, 701–708.
-
(2000)
Clin. Cancer Res
, vol.6
, pp. 701-708
-
-
Milas, L.1
Mason, K.2
Hunter, N.3
Petersen, S.4
Yamakawa, M.5
Ang, K.6
Mendelsohn, J.7
Fan, Z.8
-
25
-
-
0033561522
-
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
-
Huang, S.M.; Bock, J.M.; Harari, P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59, 1935–1940.
-
(1999)
Cancer Res
, vol.59
, pp. 1935-1940
-
-
Huang, S.M.1
Bock, J.M.2
Harari, P.M.3
-
26
-
-
33644971314
-
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm
-
Pfister, D.G.; Su, Y.B.; Kraus, D.H.; Wolden, S.L.; Lis, E.; Aliff, T.B.; Zahalsky, A.J.; Lake, S.; Needle, M.N.; Shaha, A.R.;et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol. 2006, 24, 1072–1078.
-
(2006)
J. Clin. Oncol
, vol.24
, pp. 1072-1078
-
-
Pfister, D.G.1
Su, Y.B.2
Kraus, D.H.3
Wolden, S.L.4
Lis, E.5
Aliff, T.B.6
Zahalsky, A.J.7
Lake, S.8
Needle, M.N.9
Shaha, A.R.10
-
27
-
-
32144433159
-
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
-
Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567–578.
-
(2006)
N. Engl. J. Med
, vol.354
, pp. 567-578
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
Azarnia, N.4
Shin, D.M.5
Cohen, R.B.6
Jones, C.U.7
Sur, R.8
Raben, D.9
Jassem, J.10
-
28
-
-
0026645077
-
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs.Methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study
-
Forastiere, A.A.; Metch, B.; Schuller, D.E.; Ensley, J.F.; Hutchins, L.F.; Triozzi, P.; Kish, J.A.; McClure, S.; VonFeldt, E.; Williamson, S.K. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs.methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J. Clin. Oncol. 1992, 10, 1245–1251.
-
(1992)
J. Clin. Oncol
, vol.10
, pp. 1245-1251
-
-
Forastiere, A.A.1
Metch, B.2
Schuller, D.E.3
Ensley, J.F.4
Hutchins, L.F.5
Triozzi, P.6
Kish, J.A.7
McClure, S.8
Vonfeldt, E.9
Williamson, S.K.10
-
29
-
-
23744495620
-
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy
-
Leon, X.; Hitt, R.; Constenla, M.; Rocca, A.; Stupp, R.; Kovacs, A.F.; Amellal, N.; Bessa, E.H.; Bourhis, J. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 2005, 17, 418–424.
-
(2005)
Clin. Oncol. (R. Coll. Radiol.)
, vol.17
, pp. 418-424
-
-
Leon, X.1
Hitt, R.2
Constenla, M.3
Rocca, A.4
Stupp, R.5
Kovacs, A.F.6
Amellal, N.7
Bessa, E.H.8
Bourhis, J.9
-
30
-
-
23844523253
-
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
-
Baselga, J.; Trigo, J.M.; Bourhis, J.; Tortochaux, J.; Cortes-Funes, H.; Hitt, R.; Gascon, P.; Amellal, N.; Harstrick, A.; Echkardt, A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23, 5568–5577.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 5568-5577
-
-
Baselga, J.1
Trigo, J.M.2
Bourhis, J.3
Tortochaux, J.4
Cortes-Funes, H.5
Hitt, R.6
Gascon, P.7
Amellal, N.8
Harstrick, A.9
Echkardt, A.10
-
31
-
-
24944490558
-
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
-
Herbst, R.S.; Arquette, M.; Shin, D.M.; Dicke, K.; Vokes, E.E.; Azarnia, N.; Hong, W.K.; Kies, M.S. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23, 5578–5587.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 5578-5587
-
-
Herbst, R.S.1
Arquette, M.2
Shin, D.M.3
Dicke, K.4
Vokes, E.E.5
Azarnia, N.6
Hong, W.K.7
Kies, M.S.8
-
32
-
-
33144461661
-
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study
-
Burtness, B.; Goldwasser, M.A.; Flood, W.; Mattar, B.; Forastiere, A.A.; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005, 23, 8646–8654.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 8646-8654
-
-
Burtness, B.1
Goldwasser, M.A.2
Flood, W.3
Mattar, B.4
Forastiere, A.A.5
-
33
-
-
51649085865
-
Platinum-based chemotherapy plus cetuximab in head and neck cancer
-
Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.R.; Cupissol, D.; et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359, 1116–1127.
-
(2008)
N. Engl. J. Med
, vol.359
, pp. 1116-1127
-
-
Vermorken, J.B.1
Mesia, R.2
Rivera, F.3
Remenar, E.4
Kawecki, A.5
Rottey, S.6
Erfan, J.7
Zabolotnyy, D.8
Kienzer, H.R.D.9
-
34
-
-
84859483100
-
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
-
Hitt, R.; Irigoyen, A.; Cortes-Funes, H.; Grau, J.J.; Garcia-Saenz, J.A.; Cruz-Hernandez, J.J.; Spanish Head and Neck Cancer Cooperative Groupo (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann. Oncol. 2012, 23, 1016–1022.
-
(2012)
Ann. Oncol
, vol.23
, pp. 1016-1022
-
-
Hitt, R.1
Irigoyen, A.2
Cortes-Funes, H.3
Grau, J.J.4
Garcia-Saenz, J.A.5
Cruz-Hernandez, J.J.6
-
35
-
-
84859813676
-
New promising molecular targets in head and neck squamous cell carcinoma
-
Bauman, J.E.; Michel, L.S.; Chung, C.H. New promising molecular targets in head and neck squamous cell carcinoma.Curr. Opin. Oncol. 2012, 24, 235–242.
-
(2012)
Curr. Opin. Oncol
, vol.24
, pp. 235-242
-
-
Bauman, J.E.1
Michel, L.S.2
Chung, C.H.3
-
36
-
-
84874107117
-
Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck
-
Shin, D.M.; Khuri, F.R. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2013, 35, 443–453.
-
(2013)
Head Neck
, vol.35
, pp. 443-453
-
-
Shin, D.M.1
Khuri, F.R.2
-
37
-
-
84903194826
-
Novel treatments for head and neck squamous cell carcinoma: Preclinical identification and clinical investigation
-
Bowles, D.W.; McDermott, J.D.; Jimeno, A. Novel treatments for head and neck squamous cell carcinoma: Preclinical identification and clinical investigation. Future Oncol. 2014, 10, 1065–1080.
-
(2014)
Future Oncol
, vol.10
, pp. 1065-1080
-
-
Bowles, D.W.1
McDermott, J.D.2
Jimeno, A.3
-
38
-
-
84896696623
-
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
-
Cohen, R.B. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat. Rev. 2014,40, 567–577.
-
(2014)
Cancer Treat. Rev
, vol.40
, pp. 567-577
-
-
Cohen, R.B.1
-
39
-
-
84879785532
-
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial
-
Vermorken, J.B.; Stohlmacher-Williams, J.; Davidenko, I.; Licitra, L.; Winquist, E.; Villanueva, C.; Foa, P.; Rottey, S.; Skladowski, K.; Tahara, M.; et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial.Lancet Oncol. 2013, 14, 697–710.
-
(2013)
Lancet Oncol
, vol.14
, pp. 697-710
-
-
Vermorken, J.B.1
Stohlmacher-Williams, J.2
Davidenko, I.3
Licitra, L.4
Winquist, E.5
Villanueva, C.6
Foa, P.7
Rottey, S.8
Skladowski, K.M.9
-
40
-
-
79953183347
-
Zalutumumab plus best supportive care vs. Best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomised phase 3 trial
-
Machiels, J.P.; Subramanian, S.; Ruzsa, A.; Repassy, G.; Lifirenko, I.; Flygare, A.; Sorensen, P.; Nielsen, T.; Lisby, S.; Clement, P.M. Zalutumumab plus best supportive care vs. best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomised phase 3 trial. Lancet Oncol. 2011, 12, 333–343.
-
(2011)
Lancet Oncol
, vol.12
, pp. 333-343
-
-
Machiels, J.P.1
Subramanian, S.2
Ruzsa, A.3
Repassy, G.4
Lifirenko, I.5
Flygare, A.6
Sorensen, P.7
Nielsen, T.8
Lisby, S.9
Clement, P.M.10
-
41
-
-
64649097892
-
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck
-
Stewart, J.S.; Cohen, E.E.; Licitra, L.; Van Herpen, C.M.; Khorprasert, C.; Soulieres, D.; Vodvarka, P.; Rischin, D.; Garin, A.M.; Hirsch, F.R.; et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2009, 27, 1864–1871.
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 1864-1871
-
-
Stewart, J.S.1
Cohen, E.E.2
Licitra, L.3
Van Herpen, C.M.4
Khorprasert, C.5
Soulieres, D.6
Vodvarka, P.7
Rischin, D.8
Garin, A.M.F.R.9
-
42
-
-
84876073132
-
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An eastern cooperative oncology group trial
-
Argiris, A.; Ghebremichael, M.; Gilbert, J.; Lee, J.W.; Sachidanandam, K.; Kolesar, J.M.; Burtness, B.; Forastiere, A.A. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An eastern cooperative oncology group trial. J. Clin. Oncol. 2013, 31, 1405–1414.
-
(2013)
J. Clin. Oncol
, vol.31
, pp. 1405-1414
-
-
Argiris, A.1
Ghebremichael, M.2
Gilbert, J.3
Lee, J.W.4
Sachidanandam, K.5
Kolesar, J.M.6
Burtness, B.7
Forastiere, A.A.8
-
43
-
-
1842772526
-
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
-
Soulieres, D.; Senzer, N.N.; Vokes, E.E.; Hidalgo, M.; Agarwala, S.S.; Siu, L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 2004, 22, 77–85.
-
(2004)
J. Clin. Oncol
, vol.22
, pp. 77-85
-
-
Soulieres, D.1
Senzer, N.N.2
Vokes, E.E.3
Hidalgo, M.4
Agarwala, S.S.5
Siu, L.L.6
-
44
-
-
34250208469
-
Phase I/II trial of Erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
-
Siu, L.L.; Soulieres, D.; Chen, E.X.; Pond, G.R.; Chin, S.F.; Francis, P.; Harvey, L.; Klein, M.; Zhang, W.; Dancey, J.; et al. Phase I/II trial of Erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2007, 25, 2178–2183.
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 2178-2183
-
-
Siu, L.L.1
Soulieres, D.2
Chen, E.X.3
Pond, G.R.4
Chin, S.F.5
Francis, P.6
Harvey, L.7
Klein, M.8
Zhang, W.J.9
-
45
-
-
84859873106
-
A phase II study of lapatinib in recurrent of metastatic squamous cell carcinoma of the head and neck
-
De Souza, J.A.; Davis, D.W.; Zhang, Y.; Khattri, A.; Seiwert, T.Y.; Aktolga, S.; Wong, S.J.; Kozloff, M.F.; Nattam, S.; Lingen, M.W.; et al. A phase II study of lapatinib in recurrent of metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2012, 18, 2336–2343.
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 2336-2343
-
-
De Souza, J.A.1
Davis, D.W.2
Zhang, Y.3
Khattri, A.4
Seiwert, T.Y.5
Aktolga, S.6
Wong, S.J.7
Kozloff, M.F.8
Nattam, S.M.W.9
-
46
-
-
84903764970
-
A randomized, phase II study of afatinib vs. Cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
-
Seiwert, T.Y.; Fayette, J.; Cupissol, D.; Del Campo, J.M.; Clement, P.M.; Hitt, R.; Degardin, M.; Zhang, W.; Blackman, A.; Ehrnrooth, E.; et al. A randomized, phase II study of afatinib vs. cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann. Oncol. 2014, 25, 1813–1820.
-
(2014)
Ann. Oncol
, vol.25
, pp. 1813-1820
-
-
Seiwert, T.Y.1
Fayette, J.2
Cupissol, D.3
Del Campo, J.M.4
Clement, P.M.5
Hitt, R.6
Degardin, M.7
Zhang, W.8
Blackman, A.E.9
-
47
-
-
84903244134
-
Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib vs. Methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
-
Machiels, J.P.; Licitra, L.F.; Haddad, R.I.; Tahara, M.; Cohen, E.E. Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib vs. methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer 2014, 14, 473.
-
(2014)
BMC Cancer
, vol.14
-
-
Machiels, J.P.1
Licitra, L.F.2
Haddad, R.I.3
Tahara, M.4
Cohen, E.E.5
-
48
-
-
84933678811
-
Afatinib vs. Methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial
-
Machiels, J.P.; Haddad, R.I.; Fayette, J.; Licitra, L.F.; Tahara, M.; Vermorken, J.B.; Clement, P.M.; Gauler, T.; Cupissol, D.; Grau, J.J.; et al. Afatinib vs. methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial. Lancet Oncol. 2015, 16, 583–594.
-
(2015)
Lancet Oncol
, vol.16
, pp. 583-594
-
-
Machiels, J.P.1
Haddad, R.I.2
Fayette, J.3
Licitra, L.F.4
Tahara, M.5
Vermorken, J.B.6
Clement, P.M.7
Gauler, T.8
Cupissol, D.J.J.9
-
49
-
-
84874569165
-
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
-
Abdul Razak, A.R.; Soulieres, D.; Laurie, S.A.; Hotte, S.J.; Singh, S.; Winquist, E.; Chia, S.; LeTourneau, C.; Nguyen-Tan, P.F.; Chen, E.X.; et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann. Oncol. 2013, 24, 761–769.
-
(2013)
Ann. Oncol
, vol.24
, pp. 761-769
-
-
Abdul Razak, A.R.1
Soulieres, D.2
Laurie, S.A.3
Hotte, S.J.4
Singh, S.5
Winquist, E.6
Chia, S.7
Letourneau, C.8
Nguyen-Tan, P.F.E.X.9
-
50
-
-
84964194350
-
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
-
Kim, H.S.; Kwon, H.J.; Jung, I.; Yun, M.R.; Ahn, M.J.; Kang, B.W.; Sun, J.M.; Kim, S.B.; Yoon, D.H.; Park, K.U.; et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin. Cancer Res. 2015, 21, 544–552.
-
(2015)
Clin. Cancer Res
, vol.21
, pp. 544-552
-
-
Kim, H.S.1
Kwon, H.J.2
Jung, I.3
Yun, M.R.4
Ahn, M.J.5
Kang, B.W.6
Sun, J.M.7
Kim, S.B.8
Yoon, D.H.K.U.9
-
51
-
-
84933674222
-
Targeting angiogenesis in head and neck cancer
-
Vassilakopoulou, M.; Psyrri, A.; Argiris, A. Targeting angiogenesis in head and neck cancer. Oral Oncol. 2015, 51, 409–415.
-
(2015)
Oral Oncol
, vol.51
, pp. 409-415
-
-
Vassilakopoulou, M.1
Psyrri, A.2
Argiris, A.3
-
52
-
-
84871554687
-
Cetuximab and bevacizumab: Preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
-
Argiris, A.; Kotsakis, A.P.; Hoang, T.; Worden, F.P.; Savvides, P.; Gibson, M.K.; Gyanchandani, R.; Blumenschein, G.R., Jr.; Chen, H.X.; Grandis, J.R.; et al. Cetuximab and bevacizumab: Preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. 2013, 24, 220–225.
-
(2013)
Ann. Oncol
, vol.24
, pp. 220-225
-
-
Argiris, A.1
Kotsakis, A.P.2
Hoang, T.3
Worden, F.P.4
Savvides, P.5
Gibson, M.K.6
Gyanchandani, R.7
Blumenschein, G.R.8
Chen, H.X.J.R.9
-
53
-
-
79952741923
-
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer
-
Argiris, A.; Karamouzis, M.V.; Gooding, W.E.; Branstetter, B.F.; Zhong, S.; Raez, L.E.; Savvides, P.; Romkes, M. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J. Clin. Oncol.2011, 29, 1140–1145.
-
(2011)
J. Clin. Oncol
, vol.29
, pp. 1140-1145
-
-
Argiris, A.1
Karamouzis, M.V.2
Gooding, W.E.3
Branstetter, B.F.4
Zhong, S.5
Raez, L.E.6
Savvides, P.7
Romkes, M.8
-
54
-
-
73949143686
-
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01
-
Machiels, J.P.; Henry, S.; Zanetta, S.; Kaminsky, M.C.; Michoux, N.; Rommel, D.; Schmitz, S.; Bompas, E.; Dillies, A.F.; Faivre, S.; et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J. Clin. Oncol. 2010, 28, 21–28.
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 21-28
-
-
Machiels, J.P.1
Henry, S.2
Zanetta, S.3
Kaminsky, M.C.4
Michoux, N.5
Rommel, D.6
Schmitz, S.7
Bompas, E.8
Dillies, A.F.S.9
-
55
-
-
77954754601
-
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420
-
Williamson, S.K.; Moon, J.; Huang, C.H.; Guaglianone, P.P.; LeBlanc, M.; Wolf, G.T.; Urba, S.G. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J. Clin. Oncol. 2010, 28, 3330–3335.
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 3330-3335
-
-
Williamson, S.K.1
Moon, J.2
Huang, C.H.3
Guaglianone, P.P.4
Leblanc, M.5
Wolf, G.T.6
Urba, S.G.7
-
56
-
-
84880049211
-
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
-
Limaye, S.; Riley, S.; Zhao, S.; O'Neill, A.; Posner, M.; Adkins, D.; Jaffa, Z.; Clark, J.; Haddad, R. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol. 2013, 49, 835–841.
-
(2013)
Oral Oncol
, vol.49
, pp. 835-841
-
-
Limaye, S.1
Riley, S.2
Zhao, S.3
O'neill, A.4
Posner, M.5
Adkins, D.6
Jaffa, Z.7
Clark, J.8
Haddad, R.9
-
57
-
-
84919617522
-
Sequencing the head and neck cancer genome: Implications for therapy
-
Sun, W.; Califano, J.A. Sequencing the head and neck cancer genome: Implications for therapy. Ann. N. Y. Acad. Sci.2014, 1333, 33–42.
-
(2014)
Ann. N. Y. Acad. Sci
, vol.1333
, pp. 33-42
-
-
Sun, W.1
Califano, J.A.2
-
58
-
-
84933182955
-
TEMHEAD: A single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)
-
Grunwald, V.; Keilholz, U.; Boehm, A.; Guntinas-Lichius, O.; Hennemann, B.; Schmoll, H.J.; Ivanyi, P.; Abbas, M.; Lehmann, U.; Koch, A.; et al. TEMHEAD: A single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Ann. Oncol. 2015, 26, 561–567.
-
(2015)
Ann. Oncol
, vol.26
, pp. 561-567
-
-
Grunwald, V.1
Keilholz, U.2
Boehm, A.3
Guntinas-Lichius, O.4
Hennemann, B.5
Schmoll, H.J.6
Ivanyi, P.7
Abbas, M.8
Lehmann, U.A.9
-
59
-
-
84875722517
-
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
-
Bauman, J.E.; Arias-Pulido, H.; Lee, S.J.; Fekrazad, M.H.; Ozawa, H.; Fertig, E.; Howard, J.; Bishop, J.; Wang, H.; Olson, G.T.; et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013, 49, 461–467.
-
(2013)
Oral Oncol
, vol.49
, pp. 461-467
-
-
Bauman, J.E.1
Arias-Pulido, H.2
Lee, S.J.3
Fekrazad, M.H.4
Ozawa, H.5
Fertig, E.6
Howard, J.7
Bishop, J.8
Wang, H.G.T.9
-
60
-
-
84946741673
-
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
-
Massarelli, E.; Lin, H.; Ginsberg, L.E.; Tran, H.T.; Lee, J.J.; Canales, J.R.; Williams, M.D.; Blumenschein, G.R., Jr.; Lu, C.; Heymach, J.V.; et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 2015, 26, 1476–1480.
-
(2015)
Ann. Oncol
, vol.26
, pp. 1476-1480
-
-
Massarelli, E.1
Lin, H.2
Ginsberg, L.E.3
Tran, H.T.4
Lee, J.J.5
Canales, J.R.6
Williams, M.D.7
Blumenschein, G.R.8
Lu, C.J.V.9
-
61
-
-
84933178034
-
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
-
Jimeno, A.; Bauman, J.E.; Weissman, C.; Adkins, D.; Schnadig, I.; Beauregard, P.; Bowles, D.W.; Spira, A.; Levy, B.; Seetharamu, N.; et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.Oral Oncol. 2015, 51, 383–388.
-
(2015)
Oral Oncol
, vol.51
, pp. 383-388
-
-
Jimeno, A.1
Bauman, J.E.2
Weissman, C.3
Adkins, D.4
Schnadig, I.5
Beauregard, P.6
Bowles, D.W.7
Spira, A.8
Levy, B.N.9
-
62
-
-
84933180890
-
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
-
Jimeno, A.; Shirai, K.; Choi, M.; Laskin, J.; Kochenderfer, M.; Spira, A.; Cline-Burkhardt, V.; Winquist, E.; Hausman, D.; Walker, L.; et al. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.Ann. Oncol. 2015, 26, 556–561.
-
(2015)
Ann. Oncol
, vol.26
, pp. 556-561
-
-
Jimeno, A.1
Shirai, K.2
Choi, M.3
Laskin, J.4
Kochenderfer, M.5
Spira, A.6
Cline-Burkhardt, V.7
Winquist, E.8
Hausman, D.L.9
-
63
-
-
79851495693
-
Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
-
Fury, M.G.; Baxi, S.; Shen, R.; Kelly, K.W.; Lipson, B.L.; Carlson, D.; Stambuk, H.; Haque, S.; Pfister, D.G. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 2011, 31, 249–253.
-
(2011)
Anticancer Res
, vol.31
, pp. 249-253
-
-
Fury, M.G.1
Baxi, S.2
Shen, R.3
Kelly, K.W.4
Lipson, B.L.5
Carlson, D.6
Stambuk, H.7
Haque, S.8
Pfister, D.G.9
-
64
-
-
79955487784
-
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma
-
Brooks, H.D.; Glisson, B.S.; Bekele, B.N.; Johnson, F.M.; Ginsberg, L.E.; El-Naggar, A.; Culotta, K.S.; Takebe, N.; Wright, J.; Tran, H.T.; et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.Cancer 2011, 117, 2112–2119.
-
(2011)
Cancer
, vol.117
, pp. 2112-2119
-
-
Brooks, H.D.1
Glisson, B.S.2
Bekele, B.N.3
Johnson, F.M.4
Ginsberg, L.E.5
El-Naggar, A.6
Culotta, K.S.7
Takebe, N.8
Wright, J.H.T.9
-
65
-
-
0034657336
-
The role of STATs in transcriptional control and their impact on cellular function
-
Bromberg, J.; Darnell, J.E., Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19, 2468–2473.
-
(2000)
Oncogene
, vol.19
, pp. 2468-2473
-
-
Bromberg, J.1
Darnell, J.E.2
-
66
-
-
0034658499
-
STAT signaling in head and neck cancer
-
Song, J.I.; Grandis, J.R. STAT signaling in head and neck cancer. Oncogene 2000, 19, 2489–2495.
-
(2000)
Oncogene
, vol.19
, pp. 2489-2495
-
-
Song, J.I.1
Grandis, J.R.2
-
67
-
-
34547657483
-
Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience
-
Roithmaier, S.; Haydon, A.M.; Loi, S.; Esmore, D.; Griffiths, A.; Bergin, P.; Williams, T.J.; Schwarz, M.A. Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience. J. Heart Lung Transplant. 2007,26, 845–849.
-
(2007)
J. Heart Lung Transplant
, vol.26
, pp. 845-849
-
-
Roithmaier, S.1
Haydon, A.M.2
Loi, S.3
Esmore, D.4
Griffiths, A.5
Bergin, P.6
Williams, T.J.7
Schwarz, M.A.8
-
68
-
-
84858800620
-
The immune contexture in human tumours: Impact on clinical outcome
-
Fridman, W.H.; Pages, F.; Sautes-Fridman, C.; Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 2012, 12, 298–306.
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 298-306
-
-
Fridman, W.H.1
Pages, F.2
Sautes-Fridman, C.3
Galon, J.4
-
69
-
-
79959745851
-
The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis
-
Gooden, M.J.; de Bock, G.H.; Leffers, N.; Daemen, T.; Nijman, H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br. J. Cancer 2011, 105, 93–103.
-
(2011)
Br. J. Cancer
, vol.105
, pp. 93-103
-
-
Gooden, M.J.1
De Bock, G.H.2
Leffers, N.3
Daemen, T.4
Nijman, H.W.5
-
70
-
-
33847190697
-
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas
-
McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J.2006, 26, 154–158.
-
(2006)
Iowa Orthop. J
, vol.26
, pp. 154-158
-
-
McCarthy, E.F.1
-
71
-
-
84941060350
-
Immunity in head and neck cancer
-
Schoenfeld, J.D. Immunity in head and neck cancer. Cancer Immunol. Res. 2015, 3, 12–17.
-
(2015)
Cancer Immunol. Res
, vol.3
, pp. 12-17
-
-
Schoenfeld, J.D.1
-
72
-
-
84948564453
-
Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
-
Malm, I.J.; Bruno, T.C.; Fu, J.; Zeng, Q.; Taube, J.M.; Westra, W.; Pardoll, D.; Drake, C.G.; Kim, Y.J. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. Head Neck 2015, 37, 1088–1095.
-
(2015)
Head Neck
, vol.37
, pp. 1088-1095
-
-
Malm, I.J.1
Bruno, T.C.2
Fu, J.3
Zeng, Q.4
Taube, J.M.5
Westra, W.6
Pardoll, D.7
Drake, C.G.8
Kim, Y.J.9
-
73
-
-
79955081407
-
Immune suppression in head and neck cancers: A review
-
Duray, A.; Demoulin, S.; Hubert, P.; Delvenne, P.; Saussez, S. Immune suppression in head and neck cancers: A review. Clin. Dev. Immunol. 2010, 2010.
-
(2010)
Clin. Dev. Immunol.
, vol.2010
-
-
Duray, A.1
Demoulin, S.2
Hubert, P.3
Delvenne, P.4
Saussez, S.5
-
74
-
-
46849090082
-
Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients
-
Bose, A.; Chakraborty, T.; Chakraborty, K.; Pal, S.; Baral, R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun. 2008, 8, 10.
-
(2008)
Cancer Immun
, vol.8
-
-
Bose, A.1
Chakraborty, T.2
Chakraborty, K.3
Pal, S.4
Baral, R.5
-
75
-
-
34247118386
-
Functional alteration of myeloid dendritic cells through head and neck cancer
-
Brocks, C.P.; Pries, R.; Frenzel, H.; Ernst, M.; Schlenke, P.; Wollenberg, B. Functional alteration of myeloid dendritic cells through head and neck cancer. Anticancer Res. 2007, 27, 817–824.
-
(2007)
Anticancer Res
, vol.27
, pp. 817-824
-
-
Brocks, C.P.1
Pries, R.2
Frenzel, H.3
Ernst, M.4
Schlenke, P.5
Wollenberg, B.6
-
76
-
-
33947523413
-
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma
-
Molling, J.W.; Langius, J.A.; Langendijk, J.A.; Leemans, C.R.; Bontkes, H.J.; van der Vliet, H.J.; von Blomberg, B.M.; Scheper, R.J.; van den Eertwegh, A.J. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 2007, 25, 862–868.
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 862-868
-
-
Molling, J.W.1
Langius, J.A.2
Langendijk, J.A.3
Leemans, C.R.4
Bontkes, H.J.5
Van Der Vliet, H.J.6
Von Blomberg, B.M.7
Scheper, R.J.8
Van Den Eertwegh, A.J.9
-
77
-
-
82255179501
-
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
-
Cho, Y.A.; Yoon, H.J.; Lee, J.I.; Hong, S.P.; Hong, S.D. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011, 47, 1148–1153.
-
(2011)
Oral Oncol
, vol.47
, pp. 1148-1153
-
-
Cho, Y.A.1
Yoon, H.J.2
Lee, J.I.3
Hong, S.P.4
Hong, S.D.5
-
78
-
-
79959765108
-
Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma
-
Malaspina, T.S.; Gasparoto, T.H.; Costa, M.R.; de Melo, E.F., Jr.; Ikoma, M.R.; Damante, J.H.; Cavassani, K.A.; garlet, G.P.; da Silva, J.S.; Campanelli, A.P.; et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol. Immunother. 2011, 60, 965–974.
-
(2011)
Cancer Immunol. Immunother
, vol.60
, pp. 965-974
-
-
Malaspina, T.S.1
Gasparoto, T.H.2
Costa, M.R.3
De Melo, E.F.4
Ikoma, M.R.5
Damante, J.H.6
Cavassani, K.A.7
Garlet, G.P.8
Da Silva, J.S.A.P.9
-
79
-
-
84879286045
-
CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma
-
Nordfors, C.; Grun, N.; Tertipis, N.; Ahrlund-Richter, A.; Haeggblom, L.; Sivars, L.; Du, J.; Nyberg, T.; Marklund, L.; Munck, A; Wikland, E.; et al. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur. J. Cancer 2013, 49, 2522–2530.
-
(2013)
Eur. J. Cancer
, vol.49
, pp. 2522-2530
-
-
Nordfors, C.1
Grun, N.2
Tertipis, N.3
Ahrlund-Richter, A.4
Haeggblom, L.5
Sivars, L.6
Du, J.7
Nyberg, T.8
Marklund, L.A.9
Wikland, E.10
-
80
-
-
84892948376
-
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer
-
Ward, M.J.; Thirdborough, S.M.; Mellows, T.; Riley, C.; Harris, S.; Suchak, K.; Webb, A.; Hampton, C.; Patel, N.N.; Randall, C.J.; et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br. J. Cancer 2014, 110, 489–500.
-
(2014)
Br. J. Cancer
, vol.110
, pp. 489-500
-
-
Ward, M.J.1
Thirdborough, S.M.2
Mellows, T.3
Riley, C.4
Harris, S.5
Suchak, K.6
Webb, A.7
Hampton, C.8
Patel, N.N.C.J.9
-
81
-
-
70349881470
-
Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma
-
Pretscher, D.; Distel, L.V.; Grabenbauer, G.G.; Wittlinger, M.; Buettner, M.; Niedobitek, G. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 2009, 9, 292.
-
(2009)
BMC Cancer
, vol.9
-
-
Pretscher, D.1
Distel, L.V.2
Grabenbauer, G.G.3
Wittlinger, M.4
Buettner, M.5
Niedobitek, G.6
-
82
-
-
84871966600
-
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer
-
Badoual, C.; Hans, S.; Merillon, N.; van Ryswick, C.; Ravel, P.; Benhamouda, N.; Levionnois, E.; Nizard, M.; Si-Mohamed, A.; Besnier, N.; et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013, 73, 128–138.
-
(2013)
Cancer Res
, vol.73
, pp. 128-138
-
-
Badoual, C.1
Hans, S.2
Merillon, N.3
Van Ryswick, C.4
Ravel, P.5
Benhamouda, N.6
Levionnois, E.7
Nizard, M.8
Si-Mohamed, A.N.9
-
83
-
-
84877061277
-
B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma
-
Ukpo, O.C.; Thorstad, W.L.; Lewis, J.S., Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2013, 7, 113–121.
-
(2013)
Head Neck Pathol
, vol.7
, pp. 113-121
-
-
Ukpo, O.C.1
Thorstad, W.L.2
Lewis, J.S.3
-
84
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711–723.
-
(2010)
N. Engl. J. Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O’Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.J.C.9
-
85
-
-
84908354848
-
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
-
Robert, C.; Ribas, A.; Wolchok, J.D.; Hodi, F.S.; Hamid, O.; Kefford, R.; Weber, J.S.; Joshua, A.M.; Hwu, W.J.; Gangadhar, T.C.; et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384, 1109–1117.
-
(2014)
Lancet
, vol.384
, pp. 1109-1117
-
-
Robert, C.1
Ribas, A.2
Wolchok, J.D.3
Hodi, F.S.4
Hamid, O.5
Kefford, R.6
Weber, J.S.7
Joshua, A.M.8
Hwu, W.J.T.C.9
-
86
-
-
84940606077
-
Antitumor activity and safety of pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
-
Chicago, IL, USA, 29 May–2 June
-
Seiwert, T.Y.; Haddad, R.I.; Gupta, S.; Mehra, R.; Tahara, M.; Berger, R.; Lee, S.-H.; Burtness, B.; Le, D.T.; Heath, K.; et al. Antitumor activity and safety of pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). In Proceedings of the 2015 ASCO Annual Meeting, Chicago, IL, USA, 29 May–2 June 2015.
-
(2015)
Proceedings of the 2015 ASCO Annual Meeting
-
-
Seiwert, T.Y.1
Haddad, R.I.2
Gupta, S.3
Mehra, R.4
Tahara, M.5
Berger, R.6
Lee, S.-H.7
Burtness, B.8
Le, D.T.K.9
-
87
-
-
84959392838
-
Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients
-
Chicago, IL, USA, 29 May–2 June
-
Seiwert, T.; Burtness, B.; Weiss, J.; Eder, J.P.; Yearley, J.; Murphy, E.; Nebozhyn, M.; McClanahan, T.; Ayers, M.; Lunceford, J.K.; et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. In Proceedings of the 2015 ASCO Annual Meeting, Chicago, IL, USA, 29 May–2 June 2015.
-
(2015)
Proceedings of the 2015 ASCO Annual Meeting
-
-
Seiwert, T.1
Burtness, B.2
Weiss, J.3
Eder, J.P.4
Yearley, J.5
Murphy, E.6
Nebozhyn, M.7
McClanahan, T.8
Ayers, M.J.K.9
-
88
-
-
84907521155
-
A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer
-
Seiwert, T.Y.; Burtness, B.; Weiss, J.; Gluck, I.; Eder, J.P.; Pai, S.I.; Dolled-Filhart, M.; Emancipator, K.; Pathiraja, K.; Gause, C.; et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J. Clin. Oncol. 2014, 32, 6011.
-
(2014)
J. Clin. Oncol
, vol.32
-
-
Seiwert, T.Y.1
Burtness, B.2
Weiss, J.3
Gluck, I.4
Eder, J.P.5
Pai, S.I.6
Dolled-Filhart, M.7
Emancipator, K.8
Pathiraja, K.C.9
-
89
-
-
84907521154
-
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody
-
Segal, N.H.; Antonia, S.J.; Brahmer, J.R.; Maio, M.; Blake-Haskins, A.; Li, X.; Vasselli, J.; Ibrahim, R.A.; Lutzky, J.; Khleif, S.; et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J. Clin. Oncol. 2014, 32, 5s.
-
(2014)
J. Clin. Oncol
, vol.32
-
-
Segal, N.H.1
Antonia, S.J.2
Brahmer, J.R.3
Maio, M.4
Blake-Haskins, A.5
Li, X.6
Vasselli, J.7
Ibrahim, R.A.8
Lutzky, J.S.9
-
90
-
-
65549109389
-
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years
-
Brown, D.R.; Kjaer, S.K.; Sigurdsson, K.; Iversen, O.-E.; Hernandez-Avila, M.; Wheeler, C.M.; Perez, G.; Koutsky, L.A.; Tay, E.H.; Garcia, P.; et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J. Infect. Dis 2009, 199, 926–935.
-
(2009)
J. Infect. Dis
, vol.199
, pp. 926-935
-
-
Brown, D.R.1
Kjaer, S.K.2
Sigurdsson, K.3
Iversen, O.-E.4
Hernandez-Avila, M.5
Wheeler, C.M.6
Perez, G.7
Koutsky, L.A.8
Tay, E.H.P.9
-
91
-
-
0347302952
-
Cytokines in cancer pathogenesis and cancer therapy
-
Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4, 11–22.
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 11-22
-
-
Dranoff, G.1
-
92
-
-
50249168819
-
Toll-like receptor modulation in head and neck cancer
-
Pries, R.; Wulff, S.; Wollenberg, B. Toll-like receptor modulation in head and neck cancer. Crit. Rev. Immunol. 2008, 28, 201–213.
-
(2008)
Crit. Rev. Immunol
, vol.28
, pp. 201-213
-
-
Pries, R.1
Wulff, S.2
Wollenberg, B.3
-
93
-
-
84919429527
-
Toll-like receptors and cancer, particularly oral squamous cell carcinoma
-
Rich, A.M.; Hussaini, H.M.; Parachuru, V.P.; Seymour, G.J. Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front. Immunol. 2014, 5, 464.
-
(2014)
Front. Immunol
, vol.5
-
-
Rich, A.M.1
Hussaini, H.M.2
Parachuru, V.P.3
Seymour, G.J.4
-
94
-
-
34249677845
-
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
-
Kanzler, H.; Barrat, F.J.; Hessel, E.M.; Coffman, R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13, 552–559.
-
(2007)
Nat. Med
, vol.13
, pp. 552-559
-
-
Kanzler, H.1
Barrat, F.J.2
Hessel, E.M.3
Coffman, R.L.4
-
96
-
-
84904387563
-
A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma
-
Northfelt, D.W.; Ramanathan, R.K.; Cohen, P.A.; Von Hoff, D.D.; Weiss, G.J.; Dietsch, G.N.; Manjarrez, K.L.; Randall, T.D.; Hershberg, R.M. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin. Cancer Res. 2014, 20, 3683–3691.
-
(2014)
Clin. Cancer Res
, vol.20
, pp. 3683-3691
-
-
Northfelt, D.W.1
Ramanathan, R.K.2
Cohen, P.A.3
Von Hoff, D.D.4
Weiss, G.J.5
Dietsch, G.N.6
Manjarrez, K.L.7
Randall, T.D.8
Hershberg, R.M.9
-
97
-
-
34249868241
-
Adoptive T cell therapy for cancer in the clinic
-
June, C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 2007, 117, 1466–1476.
-
(2007)
J. Clin. Invest
, vol.117
, pp. 1466-1476
-
-
June, C.H.1
-
98
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Rosenberg, S.A.; Yang, J.C.; Sherry, R.M.; Kammula, U.S.; Hughes, M.S.; Phan, G.Q.; Citrin, D.E.; Restifo, N.P.; Robbins, P.F.; Wunderich, J.R.; et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17, 4550–4557.
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
Kammula, U.S.4
Hughes, M.S.5
Phan, G.Q.6
Citrin, D.E.7
Restifo, N.P.8
Robbins, P.F.9
Wunderich, J.R.10
-
99
-
-
84863269918
-
Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy
-
Smith, C.; Tsang, J.; Beagley, L.; Chua, D.; Lee, V.; Li, V.; Moss, D.J.; Coman, W.; Chan, K.H.; Nicholls, J.; et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012, 72, 1116–1125.
-
(2012)
Cancer Res
, vol.72
, pp. 1116-1125
-
-
Smith, C.1
Tsang, J.2
Beagley, L.3
Chua, D.4
Lee, V.5
Li, V.6
Moss, D.J.7
Coman, W.8
Chan, K.H.J.9
-
100
-
-
33644788176
-
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes
-
Comoli, P.; Pedrazzoli, P.; Maccario, R.; Basso, S.; Carminati, O.; Labirio, M.; Schiavo, R.; Secondino, S.; Frasson, C.; Perotti, C.; et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 2005, 23, 8942–8949.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 8942-8949
-
-
Comoli, P.1
Pedrazzoli, P.2
Maccario, R.3
Basso, S.4
Carminati, O.5
Labirio, M.6
Schiavo, R.7
Secondino, S.8
Frasson, C.9
Perotti, C.10
-
101
-
-
84871918505
-
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies
-
Ramos, C.A.; Narala, N.; Vyas, G.M.; Leen, A.M.; Gerdemann, U.; Sturgis, E.M.; Anderson, M.K.; Savoldo, B.; Heslop, H.E.; Brenner, M.K.; et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J. Immunother. 2013, 36, 66–76.
-
(2013)
J. Immunother
, vol.36
, pp. 66-76
-
-
Ramos, C.A.1
Narala, N.2
Vyas, G.M.3
Leen, A.M.4
Gerdemann, U.5
Sturgis, E.M.6
Anderson, M.K.7
Savoldo, B.8
Heslop, H.E.M.K.9
-
102
-
-
84937517792
-
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
-
Kreimer, A.R.; Struyf, F.; del Rosario-Raymundo, M.R.; Hildesheim, A.; Skinner, S.R.; Wacholder, S.; Garland, S.M.; Herrero, R.; David, M.P.; Wheeler, C.M.; et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015, 16, 775–786.
-
(2015)
Lancet Oncol
, vol.16
, pp. 775-786
-
-
Kreimer, A.R.1
Struyf, F.2
Del Rosario-Raymundo, M.R.3
Hildesheim, A.4
Skinner, S.R.5
Wacholder, S.6
Garland, S.M.7
Herrero, R.8
David, M.P.C.M.9
-
103
-
-
84908567001
-
HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis
-
Ndiaye, C.; Mena, M.; Alemany, L.; Arbyn, M.; Castellsague, X.; Laporte, L.; Bosch, F.X.; de Sanjose, S.; Trottier, H. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis.Lancet Oncol. 2014, 15, 1319–1331.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1319-1331
-
-
Ndiaye, C.1
Mena, M.2
Alemany, L.3
Arbyn, M.4
Castellsague, X.5
Laporte, L.6
Bosch, F.X.7
De Sanjose, S.8
Trottier, H.9
-
104
-
-
0142060273
-
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma
-
Devaraj, K.; Gillison, M.L.; Wu, T.C. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit. Rev. Oral Biol. Med. 2003, 14, 345–362.
-
(2003)
Crit. Rev. Oral Biol. Med
, vol.14
, pp. 345-362
-
-
Devaraj, K.1
Gillison, M.L.2
Wu, T.C.3
-
105
-
-
84921710069
-
ADXS-HPV: A therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen
-
Cory, L.; Chu, C. ADXS-HPV: A therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum. Vaccin. Immunother. 2014, 10, 3190–3195.
-
(2014)
Hum. Vaccin. Immunother
, vol.10
, pp. 3190-3195
-
-
Cory, L.1
Chu, C.2
-
106
-
-
84959392839
-
A phase I/IIa clinical trial using a p16INK4a derived peptide as vaccine in patients with advanced human papillomavirus-associated cancer
-
National Harbor, MD, USA, 27–30 October
-
Reuschenbach, M.; Karbach, J.; Faulstich, F.; Sauer, M.; Kloor, M.; Rafiyan, M.R.; Pauligk, C.; AlBatran, S.; Jaeger, E.; von Knebel Doeberitz, M. A phase I/IIa clinical trial using a p16INK4a derived peptide as vaccine in patients with advanced human papillomavirus-associated cancer. In Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research, National Harbor, MD, USA, 27–30 October 2013.
-
(2013)
Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research
-
-
Reuschenbach, M.1
Karbach, J.2
Faulstich, F.3
Sauer, M.4
Kloor, M.5
Rafiyan, M.R.6
Pauligk, C.7
Albatran, S.8
Jaeger, E.9
Von Knebel Doeberitz, M.10
|